VCYT - Veracyte, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
26.05
+0.11 (+0.42%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close25.94
Open26.08
Bid0.00 x 800
Ask28.00 x 1200
Day's Range25.80 - 26.55
52 Week Range8.77 - 31.18
Volume299,867
Avg. Volume650,331
Market Cap1.262B
Beta (3Y Monthly)0.29
PE Ratio (TTM)N/A
EPS (TTM)-0.29
Earnings DateNov 1, 2017 - Nov 6, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.00
Trade prices are not sourced from all markets
  • Business Wire

    Veracyte Announces Publication of Clinical and Analytical Validation Data for Afirma Xpression Atlas

    The Afirma XA uses RNA whole-transcriptome sequencing to detect expressed DNA variants and RNA fusion partners in over 500 genes that are associated with thyroid cancer. The test is performed on fine needle aspiration (FNA) samples of thyroid nodules deemed suspicious for cancer by Veracyte’s Afirma Genomic Sequencing Classifier (GSC), as well as those that are suspicious for or have been diagnosed as cancer based on cytopathology.

  • Loss-Making Veracyte, Inc. (NASDAQ:VCYT) Expected To Breakeven
    Simply Wall St.

    Loss-Making Veracyte, Inc. (NASDAQ:VCYT) Expected To Breakeven

    Veracyte, Inc.'s (NASDAQ:VCYT): Veracyte, Inc. operates as a genomic diagnostics company in the United States and...

  • Business Wire

    Veracyte to Present at Upcoming Investor Conferences

    Veracyte, Inc. today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the following upcoming investor conferences:

  • Is Veracyte (NASDAQ:VCYT) A Risky Investment?
    Simply Wall St.

    Is Veracyte (NASDAQ:VCYT) A Risky Investment?

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

  • Thomson Reuters StreetEvents

    Edited Transcript of VCYT earnings conference call or presentation 30-Jul-19 9:00pm GMT

    Q2 2019 Veracyte Inc Earnings Call

  • Veracyte (VCYT) Q2 2019 Earnings Call Transcript
    Motley Fool

    Veracyte (VCYT) Q2 2019 Earnings Call Transcript

    VCYT earnings call for the period ending June 30, 2019.

  • Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates

    Veracyte (VCYT) delivered earnings and revenue surprises of 44.44% and 3.20%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Will Veracyte (VCYT) Report Negative Earnings Next Week? What You Should Know
    Zacks

    Will Veracyte (VCYT) Report Negative Earnings Next Week? What You Should Know

    Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Is Veracyte, Inc.'s (NASDAQ:VCYT) CEO Pay Justified?
    Simply Wall St.

    Is Veracyte, Inc.'s (NASDAQ:VCYT) CEO Pay Justified?

    In 2008 Bonnie Anderson was appointed CEO of Veracyte, Inc. (NASDAQ:VCYT). First, this article will compare CEO...

  • Business Wire

    Veracyte to Release Second Quarter 2019 Financial Results on July 30, 2019

    Veracyte, Inc. today announced that it will release its financial results for the second quarter 2019 after the close of market on Tuesday, July 30, 2019. Company management will host a conference call and webcast to discuss its financial results and provide a general business update at 5:00 p.m.

  • Business Wire

    Veracyte Announces Next-Generation Percepta Genomic Sequencing Classifier Now Available to Physicians for Improved Lung Cancer Diagnosis

    Veracyte, Inc. (VCYT), a leading genomic diagnostics company, today announced that it has begun making its next-generation Percepta® Genomic Sequencing Classifier (GSC) available to physicians, providing them with expanded lung cancer risk information that can further guide next steps for patients with suspicious lung nodules, as compared to the original Percepta test. The RNA whole-transcriptome sequencing-based test is Veracyte’s first commercial product to emerge since entering into the long-term strategic lung-cancer collaboration with Johnson & Johnson Innovation LLC*, which was announced in January 2019. “Lung nodules are often challenging to diagnose using traditional tools, which can lead to unnecessary invasive procedures or to delayed treatment,” said Giulia Kennedy, Ph.D., Veracyte’s chief scientific and medical officer.

  • Business Wire

    Veracyte Named a San Francisco Bay Area “Top Workplace” For Sixth Consecutive Year

    Veracyte, Inc. , a leading genomic diagnostics company, announced today that the company has been awarded a Top Workplaces 2019 honor by the Bay Area News Group for the sixth consecutive year.

  • Veracyte (VCYT) Hits Fresh High: Is There Still Room to Run?
    Zacks

    Veracyte (VCYT) Hits Fresh High: Is There Still Room to Run?

    Veracyte (VCYT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • Hedge Funds Have Never Been This Bullish On Veracyte Inc (VCYT)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Veracyte Inc (VCYT)

    We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]

  • Business Wire

    Veracyte Announces New Article Published in Cancer Cytopathology Detailing Clinical Utility of Its RNA Sequencing-Based Testing for Thyroid Cancer Diagnosis and Treatment

    The article describes how the technology behind Veracyte’s Afirma® Genomic Sequencing Classifier (GSC) and Xpression Atlas (XA) is helping to reduce unnecessary surgeries in thyroid cancer diagnosis, and also inform surgery and treatment decision-making using the same minimally invasive patient sample. The article is highlighted on the cover of the June print issue, which is scheduled to be available the week of June 17, 2019.

  • InvestorPlace

    7 Top-Rated Biotech Stocks to Invest In Today

    Tech stocks are tumbling around like they're in a washing machine. Between the trade wars and varying economic numbers, chip stock have been all over the place. While the Nasdaq Biotech Index (INDEXNASDAQ:NBI) is up 7% year to date, it was a bumpy ride through the latter part of 2018.This year, the broad biotech sector has been buffeted along with other broad market indicators, considering that the weaker-than-expected U.S. economy and the continued trade war with China have slapped a question mark over that growth market.Also, U.S. healthcare seems to be frozen in place for now, so "silver bullet" medicines aren't getting the attention they deserve. And the administrations crackdown on funding and researchers at the National Institutes of Health are also challenging since most major drug discoveries start at NIH and are then pulled into R&D efforts at biotech and pharma companies.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 High-Quality Cheap Stocks to Buy With $10 But following are seven healthy biotech stocks to buy now. They get top scores in my Portfolio Grader for their fundamentals, earnings and momentum. These seven biotechs are both big and small, the one thing they have in common is growth now and in their future. Biotech Stocks to Buy: Repligen (RGEN)Repligen Corp (NASDAQ:RGEN) has had quite a good year, up 65% in the past 12 months, and 42% year to date. If a biotech or a Big Pharma are the bakeries that sell the finished goods, RGEN is the company that sells the ingredients and tools to the bakeries.It has three divisions: Chromotography (the separation of a mixture by passing it through a suspension), Filtration and OEM Products (usually proteins used for purification and cell growth products).These "ingredients" are certainly more complex than they are for a bakery, but they're just as fundamental to building drugs and manufacturing them with quality and consistency on a large scale.With a $3.6 billion market cap, RGEN is a good sized player with exposure across the industry, so it's a leveraged played on the fundamental growth in the biotech and pharmaceutical sector. And that's a solid investment moving forward. Vertex Pharma (VRTX)Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is a big-cap pharmaceutical firm based out Boston, MA. It currently has three approved drugs to treat cystic fibrosis (CF) and has a number of drugs in the pipeline to treat other auto-immune diseases.Earlier this month it moved into the genetic therapy side of the business, expanding its relationship with CRISPR Therapeutics (CSPR) and buying gene therapy company Exonics Therapeutics.Exonics is involved in developing a gene therapy for Duchenne's muscular dystrophy (DMD). DMD is the most common form of the disease. It afflicts about 1 in 3,500 males and is usually recognized between the ages of 3 and 6 years of age. By age 10, most patients are wheelchair bound.Creating a gene therapy to resolve this rare disease would be massive. And given VRTX's history with CF, it has a very good shot. * 7 U.S. Stocks to Buy With Limited Trade War Exposure It's a relative outperformer in the big cap biotech space -- it sports a $43 billion market cap -- and is still a good value. Recro Pharma (REPH)Recro Pharma Inc (NASDAQ:REPH) is a small cap -- $206 million market cap -- that was launched in 2007. Its focus is on non-opioid, non-addictive pain and analgesics.It focuses its efforts on products for hospitals and ambulatory care facilities and works with generics to develop more effective delivery systems and more targeted markets.For example, its top-performing drug is meloxicam, an analgesic for post-operative pain that is administered intravenously. It also has an intranasal formulation of dexmedetomidine (Dex) for post-operative pain. Its third pipeline drug is fadolmidine and is similar to Dex but doesn't cross the blood-brain barrier.The stock is up 31% year to date and up 75% for the past 12 months. There's a good chance that its drugs could be fast-tracked considering the opioid crisis, which would get them to market even faster. Arrowhead Pharmaceuticals Corp (ARWR)Arrowhead Pharmaceuticals Corp (NASDAQ:ARWR) is a gene therapy biotech with a twist. Instead of using modified genes to eradicate a disease, it silences genes that are causing problems.Either way, this is a very hot sector and ARWR is one of the shining stars in the biotech heaven. It has a $2 billion market cap and has been around since 1989, which is means it has been through two or three waves of biotech booms and busts.The stock is on fire right now, up 108% year to date and 134% in the past year. Part of that is the news last October is signed a deal to license one of its drugs that targets hepatitis B to Janssen Pharmaceuticals. * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 It's pricey, but it has a lot of big new ahead of it. Veracyte (VCYT)Veracyte Inc (NASDAQ:VCYT) is also on the genetic side of the biotech sector. But it doesn't develop novel drugs, it produces genetic testing for various types of diseases.This is another new sector that is growing quickly because of the processing power now available to sequence genes and see how they tick.Right now, VCYT has genetic tests for thyroid cancer, lung cancer and a lung disease called idiopathic pulmonary fibrosis. The latter has been very hard to test for in the past, so VCYT testing is a big step forward.With a $1 billion market cap, VCYT is establishing a name for itself and already has products in the market, which is a very attractive business model compared to drug companies that will spend years and billions of dollars hoping a drug will get to the marketplace.Up and staggering 214% in the past year and 121% year to date, VCYT is just getting started. And could be a serious takeover candidate. Affimed (AFMD)Affimed NV (NASDAQ:AFMD) is a Germany-based biotech that is focused on immunotherapy work. This line of work is built on the premise that you can find a way for each individual to help combat disease using their own immune system.This is highly complex and is in earlier stages than gene therapy but it has enormous potential, especially in treating various cancers.AFMD has a proprietary ROCK(R) platform for recognizing and attacking certain types of cancers. It cancelled phase 1 studies in October of AFM11 to focus on its innate cell engager AFM24.Immuno-oncology is more than just working with a patient's immune system. It also means individualized treatment solutions for each patient. That would be a massive shift in the way disease care is viewed. And it's getting very close. * 7 Dividend Stocks That Are Worth Your Money Also, being a German company, it would have access to the European markets as well as the U.S. markets due to its partnership with Genentech. But it's a small cap with some work to do, so be patient. Incyte Corp (INCY)Incyte Corp (NASDAQ:INCY) is a Delaware-based biotech that is another good-sized player with a market cap of $16 billion.It has one drug that has been in the marketplace for years now. JAKAFI is a treatment for a rare form of bone marrow cancer and it also has a use as a treatment for host-done issues with bone marrow transplants.When you have drugs for rare diseases you have less competition and you can also charge more since there is few to no competitors but the market is also very small. But this does help start generating revenue for a company that can then use that cash to develop more drugs without burning through cash waiting for a big breakthrough.INCY has cooperative agreements with Merck (MRK) and Bristol Myers Squibb (BMY) using a new drug to work with their immuno-oncology drugs that are already on the market. This could be a big opportunity since these two Big Pharma firms could help get this combination through regulatory hurdles.The stock is up 21% year to date but only 4% in the past year. Its partnerships with leading Big Pharma firms is a strategic play on broader industry exposure.Louis Navellier is a renowned growth investor. He is the editor of five investing newsletters: Blue Chip Growth, Emerging Growth, Ultimate Growth, Family Trust and Platinum Growth. His most popular service, Blue Chip Growth, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 * 7 Value Stocks That Are Flying Under the Radar * 6 Mouth-Watering Fast Food Stocks for Growth Investors Compare Brokers The post 7 Top-Rated Biotech Stocks to Invest In Today appeared first on InvestorPlace.

  • GE wants to unload the portfolio of its Menlo Park venture arm
    American City Business Journals

    GE wants to unload the portfolio of its Menlo Park venture arm

    The corporate venture unit led rounds for a number of Bay Area startups over the past six years, including a pair of Redwood City-based unicorns — 3D-printing business Carbon Inc. and personalized medical technology developer Heartflow Inc.

  • Business Wire

    Veracyte Announces New Publication of Data Demonstrating Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis

    Findings from the clinical utility study, conducted by researchers at The Ohio State University, appear online in the journal Thyroid and add to the growing body of independent evidence demonstrating the performance of the next-generation genomic test. In the study, researchers evaluated records for all patients whose thyroid nodules were indeterminate for cancer based on cytopathology and who subsequently underwent molecular testing with the Afirma GSC or the original Afirma Gene Expression Classifier (GEC) between February 2011 and December 2018.

  • Riskalyze hires Bay Area tech executive as CFO
    American City Business Journals

    Riskalyze hires Bay Area tech executive as CFO

    The Auburn-based financial technology company has hired a chief financial officer with experience at several Bay Area technology companies.

  • New Strong Buy Stocks for June 7th
    Zacks

    New Strong Buy Stocks for June 7th

    New Strong Buy Stocks for June 7th

  • Business Wire

    Veracyte Announces New Data Showing Potential of Afirma Genomic Test to Guide Targeted Treatment for Medullary Thyroid Cancer Concurrent with Diagnosis

    The findings advance physicians’ ability to answer multiple clinical questions for their thyroid patients using a single, minimally invasive sample. Researchers used the Afirma XA to conduct RNA sequencing on 90 thyroid fine needle aspiration samples that had been diagnosed with medullary thyroid cancer (MTC) through the Afirma GSC.

  • Before You Buy Veracyte, Inc. (NASDAQ:VCYT), Consider Its Volatility
    Simply Wall St.

    Before You Buy Veracyte, Inc. (NASDAQ:VCYT), Consider Its Volatility

    Anyone researching Veracyte, Inc. (NASDAQ:VCYT) might want to consider the historical volatility of the share price...

  • Business Wire

    Veracyte Announces Participation in Two Upcoming Investor Conferences

    Veracyte, Inc. today announced that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present at two upcoming investor conferences: